MEK inhibitors have been unsuccessful both in preclinical models and in patients with resistance to BRAF inhibitors [10] suggesting that other compensatory pathways would be involved and, to date, no effective therapy that circumvents melanoma resistant to BRAF inhibitors is available. This evidence concerns the gene BRAF and melanoma.